A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 147; no. 2; p. AB137
Main Authors McKenzie, Andrew, Roberts, Anthony, Malandkar, Sourabh, Feuersenger, Henrike, Panousis, Con, Pawaskar, Dipti
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2021
Elsevier Limited
Subjects
Double-blind studies
Intravenous administration
Pharmacokinetics
Placebos
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2020.12.498